https://scholars.lib.ntu.edu.tw/handle/123456789/639592
Title: | Albumin-Bilirubin Grade Analyses of Atezolizumab plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study | Authors: | Kudo, Masatoshi Finn, Richard S ANN-LII CHENG Zhu, Andrew X Ducreux, Michel Galle, Peter R Sakamoto, Naoya Kato, Naoya Nakano, Michitaka Jia, Jing Vogel, Arndt |
Keywords: | Albumin-bilirubin grade; Atezolizumab; Bevacizumab; Unresectable hepatocellular carcinoma | Issue Date: | Oct-2023 | Journal Volume: | 12 | Journal Issue: | 5 | Source: | Liver cancer | Abstract: | Atezolizumab + bevacizumab showed survival benefit in patients with unresectable hepatocellular carcinoma (HCC) versus sorafenib in the Phase III IMbrave150 study. This exploratory analysis examined the prognostic impact of a baseline albumin-bilirubin (ALBI) score. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/639592 | ISSN: | 2235-1795 | DOI: | 10.1159/000529996 |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.